Analyst Price Target is $112.25
▲ +63.01% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $112.25, with a high forecast of $138.00 and a low forecast of $80.00. The average price target represents a 63.01% upside from the last price of $68.86.
Current Consensus is
Buy
The current consensus among 10 polled investment analysts is to buy stock in Viking Therapeutics. This Buy consensus rating has held steady for over two years.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Read More
